Celbopag 50mg Tablet

Celbopag 50mg tablet is a targeted based medicine mostly used In the treatment of hepatitis C and manage low platelet count. The medicine contains thrombopoietin receptor agonist which belongs to the drug class that help increase platelet production. Its active ingredient is Eltrombopag Olamine. It works by stimulating the bone marrow to produce more platelets. Doctor prescribed this medication under strict guidance as incorrect dosage and duration may cause serious side effects.

Treatment for hepatitis C and manage low platelet count

Every medication has certain side effects. Celbopag 50mg tablet also contains various side effects, consult the doctor if any of these side effects occur:
● Common cold
● Cough
● Respiratory tract infection
● Back pain
● High temperature, cough
● Loss of appetite
● Hair loss
● Swelling in feet or hands
● Headache, dizziness
● Mouth and throat pain
● Joint pain
● Diarrhea, abdominal pain
● Common cold

Doctor prescribed to take Celbopag 50mg tablet on an empty stomach to ensure proper absorption and effectiveness of the medication. The dosage and duration is correctly recommended to the healthcare professional. Improper use may affect the treatment outcomes so it can be taken exactly as guided by the doctor to ensure safe and effective treatment.

Celbopage 50mg is a targeted based medication, it contains thrombopoietin receptor agonist which belongs to the drug class that help increase drug production. It works similarly to the natural hormone thrombopoietin by stimulating the bone marrow to produce more platelets. It is commonly prescribed for conditions where platelet counts are low.

• Kabir, S. R., Asaduzzaman, M., Shahinuzzaman, A. D. A., & Alam, M. T. (2025). Eltrombopag olamine induces apoptosis in human breast adenocarcinoma and hepatocellular carcinoma cells through modulation of multiple apoptotic pathways. Scientific Reports.
• Wang, K., Xu, P., Lu, S., & Yao, B. (2024). Postmarketing safety of eltrombopag olamine: an analysis of the FDA Adverse Event Reporting System (FAERS).
• Hussar, D. A. (2009). New drugs: C1 inhibitor (human), romiplostim, and eltrombopag olamine. Journal of the American Pharmacists Association, 49(1), 124-127.
• Wang, J., Zhao, Z., Tao, Y., & Lan, Y. (2024). Bioequivalence and Food Effect Assessment of Eltrombopag Olamine Tablets in Healthy Chinese Subjects: An Open, Randomized, Single‐Dose, and Two‐Period Crossover Study. Clinical Pharmacology in Drug Development, 13(11), 1260-1266.
• Kaduk, J. A., Gindhart, A. M., & Blanton, T. N. (2021). Crystal structure of eltrombopag olamine form I,(C2H8NO) 2 (C25H20N4O4). Powder Diffraction, 36(2), 100-106.